Division of Cardiothoracic Surgery, Endowed Chair of Lung Cancer Research, University of Washington, Seattle, WA, USA.
Clin Chest Med. 2010 Mar;31(1):127-33, Table of Contents. doi: 10.1016/j.ccm.2009.10.002.
Prolonged pulmonary parenchymal air leaks are an important clinical problem. Standard treatment of prolonged air leaks include continued chest tube drainage, pleural sclerosis, or surgery. Approaches that are less invasive than bedside sclerosis or surgery are desirable but bronchoscopy approaches tried over the years have had limited success. In 2001, an American College of Chest Physicians (ACCP) consensus statement concluded there was no role for bronchoscopy for the treatment of prolonged air leaks. The development of bronchial valves for treatment of emphysema allowed the use of these devices for air leaks under compassionate use regulations. Multiple reports of successful bronchial valve treatments, along with the US Food and Drug Administration's (FDA) humanitarian use approval of a bronchial valve for certain postsurgical air leaks, provide new evidence that there is likely a role for endobronchial treatment of prolonged air leaks in selected patients.
持续性肺实质漏气是一个重要的临床问题。持续性肺漏气的标准治疗方法包括持续的胸腔引流、胸膜固定术或手术。比床边硬化或手术更具侵入性的方法是理想的，但多年来尝试的支气管镜方法收效甚微。2001 年，美国胸科医师学会（ACCP）的一项共识声明得出结论，支气管镜检查在治疗持续性肺漏气方面没有作用。支气管镜瓣膜的开发用于治疗肺气肿，使得在同情使用规定下可以使用这些设备治疗漏气。多项成功的支气管镜瓣膜治疗报告，以及美国食品和药物管理局（FDA）对支气管镜瓣膜用于某些手术后肺漏气的人道主义使用批准，提供了新的证据，表明在某些选定的患者中，支气管镜内治疗持续性肺漏气可能具有一定的作用。
